Elixir Medical to Release Five-year DESolve Nx Trial Data, Showcase Next-Generation Coronary and SFA Bioresorbable Scaffold Systems at EuroPCR 2017

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Long-term 5-year clinical follow-up data for the DESolve® Novolimus eluting coronary scaffold system, 6-month clinical and imaging data for the 120 µm thin-strut DESolve Cx Novolimus eluting coronary bioresorbable scaffold system, and initial clinical results of the PRAVA Bioresorbable scaffold system for SFA in the peripheral vasculature

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it will release at EuroPCR in Paris the long-term 5-year clinical follow-up data for the DESolve® Novolimus eluting coronary scaffold system, 6-month clinical and imaging data for the 120 µm thin-strut DESolve Cx Novolimus eluting coronary bioresorbable scaffold system, and initial clinical results of the PRAVA Bioresorbable scaffold system for SFA in the peripheral vasculature. EuroPCR is the annual meeting of the European Association for Percutaneous Cardiovascular Interventions.

@ElixirMed to present 5yr DESolve Nx Trial Data, Next-Gen Coronary & SFA Bioresorbable Scaffold Systems #EuroPCR2017

Tweet this

Following are some of the highlights of Elixir Medical’s scientific sessions at EuroPCR (in chronological order) at the Palais Des Congres de Paris in Central European Summer Time (CEST):

Tuesday, May 16

12:30, Room 351

Multicentre evaluation of a novel 120µm DESolve Cx BRS: first report of six-month clinical and imaging endpoints
• Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

12:45, Room 351

Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and four-year clinical and imaging results
• Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, Antwerp, Belgium

Thursday, May 18

10:41, Room Maillot, Level 2

Elixir Medical DESAPPEAR SFA Study – Initial clinical experience with the PRAVA bioresorbable scaffold system
• Koen Deloose, MD, AZ St Blasius Hospital, Dendermonde, Belgium

Friday, May 19

10:30, Room 253

Multicentre, post-marketing evaluation of the Elixir DESolve Novolimus-Eluting coronary BRS system: 12M results for the DESolve PMCF study
• Ricardo Costa, MD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil

About Elixir Medical

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company’s next-generation drug-eluting stent systems and bioresorbable coronary scaffolds are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.